Pharmacovigilance Market Analysis By Global Industry Insight Market, Size, Share, Development, Growth and Demand Forecast to 2022
The worldwide pharmacovigilance business sector is becoming altogether because of expanding sympathy toward medication wellbeing, expanding rates of unfavorable medication responses and poisonous quality, and high patient consistence for medication use. What's more, government and non-government associations are effectively included in deciding medication well being and adequacy, which thus is supporting development of worldwide pharmacovigilance market. Huge unexplored pharmacovigilance market in developing economies and expanding pharmaceutical organizations' consistence for outsourcing administrations are making adequate open doors for the worldwide pharmacovigilance market.
Pharmacovigilance is the procedure of checking and anticipating unfriendly medication responses. As indicated by the WHO, pharmacovigilance can be characterized as the science and exercises worried with the discovery, appraisal, comprehension and avoidance of unfavorable responses to pharmaceutical. Pharmacovigilance decides drug security and viability and enhances preventing so as to understand consideration and general wellbeing unfriendly medication responses. Unfavorable medication response is unsafe, unintended, and uncomfortable impacts of a medication. As per the studies led by WHO in created nations, around 5% of hospitalized patients are conceded in the healing centers because of unfavorable medication response, and 6-10% of these patients would experience the ill effects of genuine antagonistic medication responses. Pharmaceutical and biotechnology organizations are effectively included in the improvement of new medications; this makes an expanded interest for pharmacovigillance.
The worldwide pharmacovigilance business sector can be ordered as pharmacovigilance routines, administration suppliers, and diverse periods of medication improvement. In view of pharmacovigilance strategies, the pharmacovigilance business sector is ordered as unconstrained reporting, focused on unconstrained reporting, electronic wellbeing record mining, associate occasion observing, and increased unfavorable medication response reporting. In view of administration suppliers, the worldwide pharmacovigilance business sector can be ordered as in-house pharmacovigilance and contract outsourcing pharmacovigilance. The agreement outsourcing pharmacovigilance drives the worldwide pharmacovigilance showcase and is relied upon to develop at a higher rate in the coming years.
On the premise of diverse periods of clinical trial, the worldwide pharmacovigilance business sector is ordered as preclinical exploration, stage I clinical trial, stage II clinical trial, stage III clinical trial, and stage IV clinical trial. The stage IV clinical trial section drives the worldwide pharmacovigilance market.
The real drivers in the worldwide pharmacovigilance business sector are expanding rates of unfavorable medication responses and lethality, expanding quiet consistence for medication use, and expanding sympathy toward medication security and viability. What's more, expanding inclusion of government and non-government association to decide drug security and viability is impelling the development of the worldwide pharmacovigilance market. Then again, high danger of information break through outsourcing of pharmacovigilance and deficiency of gifted experts are a percentage of the variables limiting the development of the worldwide pharmacovigilance business sector to some degree.
Geologically, North America drives the worldwide pharmacovigilance market because of high frequencies of unfriendly medication responses and high administrative consistence for pharmacovigilance. Likewise, vicinity of countless and biotechnology organizations is energizing the development of the North American pharmacovigilance market. Asia-Pacific is the quickest developing locale in the worldwide pharmacovigilance market because of expanding sympathy toward medication wellbeing and viability, expanding rates of unfriendly medication responses and lethality, and expanding number of pharmaceuticals and biotechnology organizations. Additionally, the pharmacovigilance business sector is becoming quickly due high development of bland medications market in rising economies, for example, India and China.
A portion of the real players working in the worldwide pharmacovigilance business sector are Sanofi, Cognizant Technology Solutions, Accenture, Wipro Limited, F. Hoffmann-La Roche Ltd., ICON plc, Clinquest Group B.V., Pfizer Inc., PAREXEL International Corporation, Novartis AG, iGATE Corporation, GlaxoSmithKline, and Bristol-Myers Squibb Company.
Competitive Insights.
Major players of the pharmacovigilance market include Quintiles Transnational Corporation, Accenture Plc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb, PAREXEL International Corporation, Janssen Research & Development, LLC, Pharmaceutical Product Development, Inc., United BioSource Corporation, Synowlwedge LLC, Cognizant Technology Solutions Corporation, Covance Inc. and ICON, Plc. Mergers and acquisitions, entering into strategic collaborations with contract research organizations (CRO) and providing customized services are some key sustainability strategies adopted by these market players. For example, Accenture Plc., in an attempt to expand its service base pertaining to pharmacovigilance, launched accelerated R&D services focusing on delivery of streamlined and integrated functions helpful in effective product development and entered in to a partnership agreement with Oracle partner network.
Pharmacovigilance is the procedure of checking and anticipating unfriendly medication responses. As indicated by the WHO, pharmacovigilance can be characterized as the science and exercises worried with the discovery, appraisal, comprehension and avoidance of unfavorable responses to pharmaceutical. Pharmacovigilance decides drug security and viability and enhances preventing so as to understand consideration and general wellbeing unfriendly medication responses. Unfavorable medication response is unsafe, unintended, and uncomfortable impacts of a medication. As per the studies led by WHO in created nations, around 5% of hospitalized patients are conceded in the healing centers because of unfavorable medication response, and 6-10% of these patients would experience the ill effects of genuine antagonistic medication responses. Pharmaceutical and biotechnology organizations are effectively included in the improvement of new medications; this makes an expanded interest for pharmacovigillance.
The worldwide pharmacovigilance business sector can be ordered as pharmacovigilance routines, administration suppliers, and diverse periods of medication improvement. In view of pharmacovigilance strategies, the pharmacovigilance business sector is ordered as unconstrained reporting, focused on unconstrained reporting, electronic wellbeing record mining, associate occasion observing, and increased unfavorable medication response reporting. In view of administration suppliers, the worldwide pharmacovigilance business sector can be ordered as in-house pharmacovigilance and contract outsourcing pharmacovigilance. The agreement outsourcing pharmacovigilance drives the worldwide pharmacovigilance showcase and is relied upon to develop at a higher rate in the coming years.
On the premise of diverse periods of clinical trial, the worldwide pharmacovigilance business sector is ordered as preclinical exploration, stage I clinical trial, stage II clinical trial, stage III clinical trial, and stage IV clinical trial. The stage IV clinical trial section drives the worldwide pharmacovigilance market.
The real drivers in the worldwide pharmacovigilance business sector are expanding rates of unfavorable medication responses and lethality, expanding quiet consistence for medication use, and expanding sympathy toward medication security and viability. What's more, expanding inclusion of government and non-government association to decide drug security and viability is impelling the development of the worldwide pharmacovigilance market. Then again, high danger of information break through outsourcing of pharmacovigilance and deficiency of gifted experts are a percentage of the variables limiting the development of the worldwide pharmacovigilance business sector to some degree.
Geologically, North America drives the worldwide pharmacovigilance market because of high frequencies of unfriendly medication responses and high administrative consistence for pharmacovigilance. Likewise, vicinity of countless and biotechnology organizations is energizing the development of the North American pharmacovigilance market. Asia-Pacific is the quickest developing locale in the worldwide pharmacovigilance market because of expanding sympathy toward medication wellbeing and viability, expanding rates of unfriendly medication responses and lethality, and expanding number of pharmaceuticals and biotechnology organizations. Additionally, the pharmacovigilance business sector is becoming quickly due high development of bland medications market in rising economies, for example, India and China.
A portion of the real players working in the worldwide pharmacovigilance business sector are Sanofi, Cognizant Technology Solutions, Accenture, Wipro Limited, F. Hoffmann-La Roche Ltd., ICON plc, Clinquest Group B.V., Pfizer Inc., PAREXEL International Corporation, Novartis AG, iGATE Corporation, GlaxoSmithKline, and Bristol-Myers Squibb Company.
Competitive Insights.
Major players of the pharmacovigilance market include Quintiles Transnational Corporation, Accenture Plc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb, PAREXEL International Corporation, Janssen Research & Development, LLC, Pharmaceutical Product Development, Inc., United BioSource Corporation, Synowlwedge LLC, Cognizant Technology Solutions Corporation, Covance Inc. and ICON, Plc. Mergers and acquisitions, entering into strategic collaborations with contract research organizations (CRO) and providing customized services are some key sustainability strategies adopted by these market players. For example, Accenture Plc., in an attempt to expand its service base pertaining to pharmacovigilance, launched accelerated R&D services focusing on delivery of streamlined and integrated functions helpful in effective product development and entered in to a partnership agreement with Oracle partner network.
CHAPTER 1. EXECUTIVE SUMMARY
1.1. Pharmacovigilance– Industry Summary and Critical Success Factors (CSFs)
CHAPTER 2. PHARMACOVIGILANCE INDUSTRY OUTLOOK
2.1. Market Segmentation
2.2. Market Size and Growth Prospects
2.3. Pharmacovigilance – Market dynamics
2.3.1. Market Driver Analysis
2.3.2. Market Restraint Analysis
2.4. Key Opportunities Prioritized
2.5. Pharmacovigilance – PESTEL Analysis
2.6. Pharmacovigilance Company Market Share Analysis, 2015
CHAPTER 3. PHARMACOVIGILANCE CLINICAL TRIAL PHASE OUTLOOK
3.1. Pharmacovigilance market share, by clinical trial phase, 2015 & 2022
3.2. Preclinical
3.2.1. Preclinical Market Estimates and Forecasts, 2015 – 2022 (USD Million)
3.3. Phase
3.3.1. Phase 0 Market Estimates and Forecasts, 2015 – 2022 (USD Million)
3.4. Phase I
3.4.1. Phase I Market Estimates and Forecasts, 2015 – 2022 (USD Million)
3.5. Phase II
3.5.1. Phase II Market Estimates and Forecasts, 2015 – 2022 (USD Million)
3.6. Phase III
3.6.1. Phase III Market Estimates and Forecasts, 2015 – 2022 (USD Million)
3.7. Phase IV
3.7.1. Phase IV Market Estimates and Forecasts, 2015 – 2022 (USD Million)
CHAPTER 4. PHARMACOVIGILANCE TYPE OF SERVICE PROVIDER OUTLOOK
4.1. Pharmacovigilance market share, by type of service provider, 2016 & 2022
4.2. In- House
4.2.1. In-House Market Estimates and Forecasts, 2015 – 2022 (USD Million)
4.3. Contract Outsourcing
4.3.1. Contract Outsourcing Market Estimates and Forecasts, 2015 – 2022 (USD Million)
CHAPTER 5. PHARMACOVIGILANCE REGIONAL OUTLOOK
5.1. Pharmacovigilance market share by region, 2015 & 2022
5.2. North America
5.2.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.2.2. Market Estimates and Forecasts, by Type of Service Provider
5.3. Europe
5.3.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.3.2. Market Estimates and Forecasts, by Type of Service Provider
5.4. Asia Pacific
5.4.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.4.2. Market Estimates and Forecasts, by Type of Service Provider
5.5. RoW
5.5.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.5.2. Market Estimates and Forecasts, by Type of Service Provider
CHAPTER 6. COMPETITIVE LANDSCAPE
6.1 Accenture Plc.
6.1.1 Company Overview
6.1.2 Financial Performance
6.1.3 Product Benchmarking
6.1.4 Strategic Initiatives
6.2 Boehringer Ingelheim GmbH
6.2.1 Company Overview
6.2.2 Financial Performance
6.2.3 Product Benchmarking
6.2.4 Strategic Initiatives
6.3 Bristol-Myers Squibb
6.3.1 Company Overview
6.3.2 Financial Performance
6.3.3 Product Benchmarking
6.3.4 Strategic Initiatives
6.4 Clinquest Group B.V.
6.4.1 Company Overview
6.4.2 Financial Performance
6.4.3 Product Benchmarking
6.4.4 Strategic Initiatives
6.5 Cognizant Technology Solutions Corporation
6.5.1 Company Overview
6.5.2 Financial Performance
6.5.3 Product Benchmarking
6.5.4 Strategic Initiatives
6.6 Covance, Inc.
6.6.1 Company Overview
6.6.2 Financial Performance
6.6.3 Product Benchmarking
6.6.4 Strategic Initiatives
6.7 F. Hoffmann-La Roche Ltd
6.7.1 Company Overview
6.7.2 Financial Performance
6.7.3 Product Benchmarking
6.7.4 Strategic Initiatives
6.8 GlaxoSmithKline (GSK)
6.8.1 Company Overview
6.8.2 Financial Performance
6.8.3 Product Benchmarking
6.8.4 Strategic Initiatives
6.9 IBM Corporation
6.9.1 Company Overview
6.9.2 Financial Performance
6.9.3 Product Benchmarking
6.9.4 Strategic Initiatives
6.10 ICON, Plc
6.10.1 Company Overview
6.10.2 Financial Performance
6.10.3 Product Benchmarking
6.10.4 Strategic Initiatives
6.11 iGATE Corporation
6.11.1 Company Overview
6.11.2 Financial Performance
6.11.3 Product Benchmarking
6.11.4 Strategic Initiatives
6.12 iMEDGlobal Corporation
6.12.1 Company Overview
6.12.2 Financial Performance
6.12.3 Product Benchmarking
6.12.4 Strategic Initiatives
6.13 Infosys
6.13.1 Company Overview
6.13.2 Financial Performance
6.13.3 Product Benchmarking
6.13.4 Strategic Initiatives
6.14 Ipca Laboratories Ltd
6.14.1 Company Overview
6.14.2 Financial Performance
6.14.3 Product Benchmarking
6.14.4 Strategic Initiatives
6.15 Janssen Research & Development, LLC
6.15.1 Company Overview
6.15.2 Financial Performance
6.15.3 Product Benchmarking
6.15.4 Strategic Initiatives
6.16 Novartis International AG
6.16.1 Company Overview
6.16.2 Financial Performance
6.16.3 Product Benchmarking
6.16.4 Strategic Initiatives
6.17 PAREXEL International Corporation
6.17.1 Company Overview
6.17.2 Financial Performance
6.17.3 Product Benchmarking
6.17.4 Strategic Initiatives
6.18 Pfizer, Inc.
6.18.1 Company Overview
6.18.2 Financial Performance
6.18.3 Product Benchmarking
6.18.4 Strategic Initiatives
6.19 Pharmaceutical Product Development, Inc. (PPD, Inc.)
6.19.1 Company Overview
6.19.2 Financial Performance
6.19.3 Product Benchmarking
6.19.4 Strategic Initiatives
6.20 Sanofi Aventis
6.20.1 Company Overview
6.20.2 Financial Performance
6.20.3 Product Benchmarking
6.20.4 Strategic Initiatives
6.21 Synowlwedge LLC
6.21.1 Company Overview
6.21.2 Financial Performance
6.21.3 Product Benchmarking
6.21.4 Strategic Initiatives
6.22 Wipro Ltd.
6.22.1 Company Overview
6.22.2 Financial Performance
6.22.3 Product Benchmarking
6.22.4 Strategic Initiatives
6.23 PRA Health Sciences Inc.
6.23.1 Company Overview
6.23.2 Financial Performance
6.23.3 Product Benchmarking
6.23.4 Strategic Initiatives
6.24 Quantum Solutions India
6.24.1 Company Overview
6.24.2 Financial Performance
6.24.3 Product Benchmarking
6.24.4 Strategic Initiatives
6.25 Quintiles Transnational Corporation
6.25.1 Company Overview
6.25.2 Financial Performance
6.25.3 Product Benchmarking
6.25.4 Strategic Initiatives
6.26 inVentiv Health Inc.
6.26.1 Company Overview
6.26.2 Financial Performance
6.26.3 Product Benchmarking
6.26.4 Strategic Initiatives
6.27 OptumInsight, Inc.
6.27.1 Company Overview
6.27.2 Financial Performance
6.27.3 Product Benchmarking
6.27.4 Strategic Initiatives
6.28 United BioSource Corporation
6.28.1 Company Overview
6.28.2 Financial Performance
6.28.3 Product Benchmarking
6.28.4 Strategic Initiatives
6.29 Ecron Acunova
6.29.1 Company Overview
6.29.2 Financial Performance
6.29.3 Product Benchmarking
6.29.4 Strategic Initiatives
6.30 Fortitude Clinical
6.30.1 Company Overview
6.30.2 Financial Performance
6.30.3 Product Benchmarking
6.30.4 Strategic Initiatives
6.31 ITClinical
6.31.1 Company Overview
6.31.2 Financial Performance
6.31.3 Product Benchmarking
6.31.4 Strategic Initiatives
CHAPTER 7. METHODOLOGY AND SCOPE
7.1. Research Methodology
7.2. Research Scope & Assumption
7.3. List of Data Sources
1.1. Pharmacovigilance– Industry Summary and Critical Success Factors (CSFs)
CHAPTER 2. PHARMACOVIGILANCE INDUSTRY OUTLOOK
2.1. Market Segmentation
2.2. Market Size and Growth Prospects
2.3. Pharmacovigilance – Market dynamics
2.3.1. Market Driver Analysis
2.3.2. Market Restraint Analysis
2.4. Key Opportunities Prioritized
2.5. Pharmacovigilance – PESTEL Analysis
2.6. Pharmacovigilance Company Market Share Analysis, 2015
CHAPTER 3. PHARMACOVIGILANCE CLINICAL TRIAL PHASE OUTLOOK
3.1. Pharmacovigilance market share, by clinical trial phase, 2015 & 2022
3.2. Preclinical
3.2.1. Preclinical Market Estimates and Forecasts, 2015 – 2022 (USD Million)
3.3. Phase
3.3.1. Phase 0 Market Estimates and Forecasts, 2015 – 2022 (USD Million)
3.4. Phase I
3.4.1. Phase I Market Estimates and Forecasts, 2015 – 2022 (USD Million)
3.5. Phase II
3.5.1. Phase II Market Estimates and Forecasts, 2015 – 2022 (USD Million)
3.6. Phase III
3.6.1. Phase III Market Estimates and Forecasts, 2015 – 2022 (USD Million)
3.7. Phase IV
3.7.1. Phase IV Market Estimates and Forecasts, 2015 – 2022 (USD Million)
CHAPTER 4. PHARMACOVIGILANCE TYPE OF SERVICE PROVIDER OUTLOOK
4.1. Pharmacovigilance market share, by type of service provider, 2016 & 2022
4.2. In- House
4.2.1. In-House Market Estimates and Forecasts, 2015 – 2022 (USD Million)
4.3. Contract Outsourcing
4.3.1. Contract Outsourcing Market Estimates and Forecasts, 2015 – 2022 (USD Million)
CHAPTER 5. PHARMACOVIGILANCE REGIONAL OUTLOOK
5.1. Pharmacovigilance market share by region, 2015 & 2022
5.2. North America
5.2.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.2.2. Market Estimates and Forecasts, by Type of Service Provider
5.3. Europe
5.3.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.3.2. Market Estimates and Forecasts, by Type of Service Provider
5.4. Asia Pacific
5.4.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.4.2. Market Estimates and Forecasts, by Type of Service Provider
5.5. RoW
5.5.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.5.2. Market Estimates and Forecasts, by Type of Service Provider
CHAPTER 6. COMPETITIVE LANDSCAPE
6.1 Accenture Plc.
6.1.1 Company Overview
6.1.2 Financial Performance
6.1.3 Product Benchmarking
6.1.4 Strategic Initiatives
6.2 Boehringer Ingelheim GmbH
6.2.1 Company Overview
6.2.2 Financial Performance
6.2.3 Product Benchmarking
6.2.4 Strategic Initiatives
6.3 Bristol-Myers Squibb
6.3.1 Company Overview
6.3.2 Financial Performance
6.3.3 Product Benchmarking
6.3.4 Strategic Initiatives
6.4 Clinquest Group B.V.
6.4.1 Company Overview
6.4.2 Financial Performance
6.4.3 Product Benchmarking
6.4.4 Strategic Initiatives
6.5 Cognizant Technology Solutions Corporation
6.5.1 Company Overview
6.5.2 Financial Performance
6.5.3 Product Benchmarking
6.5.4 Strategic Initiatives
6.6 Covance, Inc.
6.6.1 Company Overview
6.6.2 Financial Performance
6.6.3 Product Benchmarking
6.6.4 Strategic Initiatives
6.7 F. Hoffmann-La Roche Ltd
6.7.1 Company Overview
6.7.2 Financial Performance
6.7.3 Product Benchmarking
6.7.4 Strategic Initiatives
6.8 GlaxoSmithKline (GSK)
6.8.1 Company Overview
6.8.2 Financial Performance
6.8.3 Product Benchmarking
6.8.4 Strategic Initiatives
6.9 IBM Corporation
6.9.1 Company Overview
6.9.2 Financial Performance
6.9.3 Product Benchmarking
6.9.4 Strategic Initiatives
6.10 ICON, Plc
6.10.1 Company Overview
6.10.2 Financial Performance
6.10.3 Product Benchmarking
6.10.4 Strategic Initiatives
6.11 iGATE Corporation
6.11.1 Company Overview
6.11.2 Financial Performance
6.11.3 Product Benchmarking
6.11.4 Strategic Initiatives
6.12 iMEDGlobal Corporation
6.12.1 Company Overview
6.12.2 Financial Performance
6.12.3 Product Benchmarking
6.12.4 Strategic Initiatives
6.13 Infosys
6.13.1 Company Overview
6.13.2 Financial Performance
6.13.3 Product Benchmarking
6.13.4 Strategic Initiatives
6.14 Ipca Laboratories Ltd
6.14.1 Company Overview
6.14.2 Financial Performance
6.14.3 Product Benchmarking
6.14.4 Strategic Initiatives
6.15 Janssen Research & Development, LLC
6.15.1 Company Overview
6.15.2 Financial Performance
6.15.3 Product Benchmarking
6.15.4 Strategic Initiatives
6.16 Novartis International AG
6.16.1 Company Overview
6.16.2 Financial Performance
6.16.3 Product Benchmarking
6.16.4 Strategic Initiatives
6.17 PAREXEL International Corporation
6.17.1 Company Overview
6.17.2 Financial Performance
6.17.3 Product Benchmarking
6.17.4 Strategic Initiatives
6.18 Pfizer, Inc.
6.18.1 Company Overview
6.18.2 Financial Performance
6.18.3 Product Benchmarking
6.18.4 Strategic Initiatives
6.19 Pharmaceutical Product Development, Inc. (PPD, Inc.)
6.19.1 Company Overview
6.19.2 Financial Performance
6.19.3 Product Benchmarking
6.19.4 Strategic Initiatives
6.20 Sanofi Aventis
6.20.1 Company Overview
6.20.2 Financial Performance
6.20.3 Product Benchmarking
6.20.4 Strategic Initiatives
6.21 Synowlwedge LLC
6.21.1 Company Overview
6.21.2 Financial Performance
6.21.3 Product Benchmarking
6.21.4 Strategic Initiatives
6.22 Wipro Ltd.
6.22.1 Company Overview
6.22.2 Financial Performance
6.22.3 Product Benchmarking
6.22.4 Strategic Initiatives
6.23 PRA Health Sciences Inc.
6.23.1 Company Overview
6.23.2 Financial Performance
6.23.3 Product Benchmarking
6.23.4 Strategic Initiatives
6.24 Quantum Solutions India
6.24.1 Company Overview
6.24.2 Financial Performance
6.24.3 Product Benchmarking
6.24.4 Strategic Initiatives
6.25 Quintiles Transnational Corporation
6.25.1 Company Overview
6.25.2 Financial Performance
6.25.3 Product Benchmarking
6.25.4 Strategic Initiatives
6.26 inVentiv Health Inc.
6.26.1 Company Overview
6.26.2 Financial Performance
6.26.3 Product Benchmarking
6.26.4 Strategic Initiatives
6.27 OptumInsight, Inc.
6.27.1 Company Overview
6.27.2 Financial Performance
6.27.3 Product Benchmarking
6.27.4 Strategic Initiatives
6.28 United BioSource Corporation
6.28.1 Company Overview
6.28.2 Financial Performance
6.28.3 Product Benchmarking
6.28.4 Strategic Initiatives
6.29 Ecron Acunova
6.29.1 Company Overview
6.29.2 Financial Performance
6.29.3 Product Benchmarking
6.29.4 Strategic Initiatives
6.30 Fortitude Clinical
6.30.1 Company Overview
6.30.2 Financial Performance
6.30.3 Product Benchmarking
6.30.4 Strategic Initiatives
6.31 ITClinical
6.31.1 Company Overview
6.31.2 Financial Performance
6.31.3 Product Benchmarking
6.31.4 Strategic Initiatives
CHAPTER 7. METHODOLOGY AND SCOPE
7.1. Research Methodology
7.2. Research Scope & Assumption
7.3. List of Data Sources
